Amgen's once-dismissed osteoporosis drug Evenity 'back in the game' after rosy FDA panel vote

If you thought Amgen osteoporosis candidate Evenity (romosozumab) was down for the count, think again.

After an overwhelmingly positive 18-1 vote in favor of approval from an FDA advisory panel Wednesday afternoon, the drug is “back in the game,” as Jefferies analyst Michael Yee put it in a note to clients.